Pacira’s Corporate Espionage- How could the SEC Fall for Pacira’s Consultants claims?
In the winter 2016, the flood of Pacira sales resumes into PixarBio was thought to be a direct result of Pacira’s slow sales of Exparel. Their Global sales leader told me “we have 95% brand recognition yet single digit sales growth, the product is not being accepted by the market”
Year over year sales of Exparel were dropping dramatically, even though they were the only non-opiate drug FDA approved for post-surgical pain during a “war on opiates”. Pacira’s Exparel sales were dropping as the direct result of a product called Exparel that was not removing opiates from the post-surgical pain mgmt. cycle. With a median time to first opiate intake after surgery at just 15 hours. The
Pacira salesforce was giving up on Exparel, even though Exparel is the only non-opiate drug that is FDA
approved for post-surgical pain Pacira Targets PixarBio
Pacira’s Sales employees pursued PixarBio aggressively. In a short period of time we hired former Pacira Sales person Glenn Reiser and Taunia Markvicka. On Taunia’s third day with PixarBio, she revealed she had a contract that paid her over $1,000,000 in 2016 to write reports on PixarBio for Pacira Pharmaceutical, while she worked at PixarBio. She told us this after a 3 hour science review of
NeuroRelease. Taunia completed her science transfer meetings and drove home to Pacira on her third
day of working at PixarBio. A pure theft of corporate knowledge. The unusual encounter with the Taunia, led PixarBio filed charges in NJ against Taunia Markvicka in
spring 2016. Former Pacira sales person David Kaplan then called PixarBio complaining he had no equity in Pacira and if we gave him equity in PixarBio he would work for PixarBio. Shortly after David Kaplan joined PixarBio
he began calling loyal PixarBio employees suggesting they quit PixarBio. David Kaplan then brought on Dr Moed Azzam who worked as an advisor at Pacira and Moed was the caller who made baseless claims to the SEC. Moed Azaam was clueless about PixarBio’s team, business, and operations as he attended two short meetings during his time working for PixarBio
The Four Former Pacira Staff that undermined PixarBio for Pacira are:
1. Moed Azzam- Attended two short PXRB meetings as a PixarBio advisor. Signed as The #1 Plaintiff in the NJ Class Action. Moed Azzam does not legally qualified to be the lead plaintiff
2. David Kaplan- David lied about relationship with Pacira, David is a real fraud who lied almost every time his lips were moving
3. Taunia Markvicka- A failed sales manager at Pacira Taunia lied about successfully rolling out Exparel, when in fact she was fired for failing to successfully roll out Exparel. Taunia came to work for PixarBio lying about still being under contract for Pacira
4. Glenn Reiser – Glenn claimed to be Pacira US Sales manager during interviews, but background checks found he was local sales rep for Pacira. Glenn had Pacira people lie to confirm his fake background. Glenn brought the rest of the Pacira team to PixarBio. LIAR
In the winter 2016, the flood of Pacira sales resumes into PixarBio was thought to be a direct result of Pacira’s slow sales of Exparel. Their Global sales leader told me “we have 95% brand recognition yet single digit sales growth, the product is not being accepted by the market”
Year over year sales of Exparel were dropping dramatically, even though they were the only non-opiate drug FDA approved for post-surgical pain during a “war on opiates”. Pacira’s Exparel sales were dropping as the direct result of a product called Exparel that was not removing opiates from the post-surgical pain mgmt. cycle. With a median time to first opiate intake after surgery at just 15 hours. The
Pacira salesforce was giving up on Exparel, even though Exparel is the only non-opiate drug that is FDA
approved for post-surgical pain Pacira Targets PixarBio
Pacira’s Sales employees pursued PixarBio aggressively. In a short period of time we hired former Pacira Sales person Glenn Reiser and Taunia Markvicka. On Taunia’s third day with PixarBio, she revealed she had a contract that paid her over $1,000,000 in 2016 to write reports on PixarBio for Pacira Pharmaceutical, while she worked at PixarBio. She told us this after a 3 hour science review of
NeuroRelease. Taunia completed her science transfer meetings and drove home to Pacira on her third
day of working at PixarBio. A pure theft of corporate knowledge. The unusual encounter with the Taunia, led PixarBio filed charges in NJ against Taunia Markvicka in
spring 2016. Former Pacira sales person David Kaplan then called PixarBio complaining he had no equity in Pacira and if we gave him equity in PixarBio he would work for PixarBio. Shortly after David Kaplan joined PixarBio
he began calling loyal PixarBio employees suggesting they quit PixarBio. David Kaplan then brought on Dr Moed Azzam who worked as an advisor at Pacira and Moed was the caller who made baseless claims to the SEC. Moed Azaam was clueless about PixarBio’s team, business, and operations as he attended two short meetings during his time working for PixarBio
The Four Former Pacira Staff that undermined PixarBio for Pacira are:
1. Moed Azzam- Attended two short PXRB meetings as a PixarBio advisor. Signed as The #1 Plaintiff in the NJ Class Action. Moed Azzam does not legally qualified to be the lead plaintiff
2. David Kaplan- David lied about relationship with Pacira, David is a real fraud who lied almost every time his lips were moving
3. Taunia Markvicka- A failed sales manager at Pacira Taunia lied about successfully rolling out Exparel, when in fact she was fired for failing to successfully roll out Exparel. Taunia came to work for PixarBio lying about still being under contract for Pacira
4. Glenn Reiser – Glenn claimed to be Pacira US Sales manager during interviews, but background checks found he was local sales rep for Pacira. Glenn had Pacira people lie to confirm his fake background. Glenn brought the rest of the Pacira team to PixarBio. LIAR